Page 275 - Haematologica May 2020

Different functions for FXII and PK in sepsis
10. Nicola H. The role of contact system in sep- tic shock: the next target? An overview of the current evidence. J Intensive Care. 2017;5(1):31.
11. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombo- sis in mice without increased risk of bleed- ing. Blood. 2011;118(19):5302–5311.
12. Oehmcke S, Westman J, Malmström J, et al. A novel role for pro-coagulant microvesicles in the early host defense against streptococcus pyogenes. PLoS Pathog. 2013;9(8):e1003529.
13. Isenring J, Köhler J, Nakata M, et al. Streptococcus gallolyticus subsp. gallolyti- cus endocarditis isolate interferes with coagulation and activates the contact sys- tem. Virulence. 2017;9(1):1–31.
14. Trepesch C, Nitzsche R, Glass A, et al. High intravascular tissue factor-but not extracel- lular microvesicles-in septic patients is associated with a high SAPS II score. J Intensive Care. 2016;4:34.
15. Sriskandan S, Cohen J. Kallikrein-kinin sys- tem activation in streptococcal toxic shock syndrome. Clin Infect Dis. 2000;30(6):961– 962.
16. Citarella F, Felici A, Brouwer M, et al. Interleukin-6 downregulates factor XII pro- duction by human hepatoma cell line (HepG2). Blood. 1997;90(4):1501–1507.
17. Bhattacharjee G, Revenko AS, Crosby JR, et al. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. Nucleic Acid Ther. 2013;23(3):175–187.
18. Aslan A, van den Heuvel MC, Stegeman CA, et al. Kidney histopathology in lethal human sepsis. Crit Care. 2018;22(1):359.
19. Wanaka K, Okamoto S, Bohgaki M, et al. Effect of a highly selective plasma- kallikrein synthetic inhibitor on contact activation relating to kinin generation, coagulation and fibrinolysis. Thromb Res. 1990;57(6):889–895.
20. Wulf RJ, Mertz ET. Studies on Plasminogen .8. Species Specificity of Streptokinase. Can
J Biochem. 1969;47(10):927–931.
21. Shannon O, Rydengård V, Schmidtchen A, et al. Histidine-rich glycoprotein promotes bacterial entrapment in clots and decreases mortality in a mouse model of sepsis.
Blood. 2010;116(13):2365–2372.
22. Colman RW. Activation of plasminogen by human plasma kallikrein. Biochem Biophys
Res Commun. 1969;35(2):273–279.
23. Nitzsche R, Rosenheinrich M, Kreikemeyer B, Oehmcke-Hecht S. Streptococcus pyo- genes triggers activation of the human con- tact system by streptokinase. Infect
Immun. 2015;83(8):3035–3042.
24. Stavrou EX, Fang C, Merkulova A, et al.
Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood. 2015;125(4):710–719.
25. Mosevoll KA, Skrede S, Markussen DL, et al. Inflammatory Mediator Profiles Differ in Sepsis Patients With and Without Bacteremia. Front Immunol. 2018;9:691.
26. Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D. Cytokine cascade in sep- sis. Scand J Infect Dis. 2003;35(9):535–544.
27. Ng PC, Li K, Leung TF, et al. Early predic- tion of sepsis-induced disseminated intravascular coagulation with interleukin- 10, interleukin-6, and RANTES in preterm infants. Clin Chem. 2006;52(6):1181–1189.
28. Konings J, Govers-Riemslag JWP, Philippou H, et al. Factor XIIa regulates the structure of the fibrin clot independently of throm- bin generation through direct interaction with fibrin. Blood. 2011;118(14):3942– 3951.
29. Konings J, Hoving LR, Ariëns RS, et al. The role of activated coagulation factor XII in overall clot stability and fibrinolysis. Thromb Res. 2015;136(2):474–480.
30. Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271–281.
31. Pluthero FG, Ryan C, Williams S, Brandão LR, Kahr WHA. Decreased in vitro throm- bin generation and clot stability in human
FXII-null blood and plasma. Br J Haematol.
2011;152(1):111–112.
32. Stroo I, Zeerleder S, Ding C, et al.
Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation. Thromb Haemost. 2017;117(8):1601–1614.
33. Mason JW, Kleeberg U, Dolan P, Colman RW. Plasma kallikrein and Hageman factor in Gram-negative bacteremia. Ann Intern Med. 1970;73(4):545–551.
34. Aasen AO, Smith-Erichsen N, Amundsen E. Plasma kallikrein-kinin system in sep- ticemia. Arch Surg. 1983;118(3):343–346.
35. Martins B, Kouyoumdjian M, Limaos EA, Borges DR. The Clearance Rate of Plasma Kallikrein by the Liver Increases During the Acute-Phase Response to Inflammation. Agents Actions. 1992;37(1-2):111–113.
36. Niessen RW, Lamping RJ, Jansen PM, et al. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost. 1997;78(3):1088–1092.
37. Sato T, Miwa T, Akatsu H, et al. Pro-car- boxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol. 2000;165(2):1053–1058.
38. Renckens R, Roelofs JJTH, Bonta PI, et al. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Blood. 2007;109(4):1593–1601.
39. Kager LM, Wiersinga WJ, Roelofs JJTH, et al. Plasminogen activator inhibitor type I contributes to protective immunity during experimental Gram-negative sepsis (melioi- dosis). J Thromb Haemost. 2011;9(10):2020–2028.
40. Renné T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of fac- tor XII. Blood. 2012;120(22):4296–4303.
41. Oehmcke S, Herwald H. Contact system activation in severe infectious diseases. J Mol Med. 2010;88(2):121–126.
42. Hess R, Wujak L, Hesse C, et al. Coagulation factor XII regulates inflamma- tory responses in human lungs. Thromb Haemost. 2017;117(10):1896–1907.
haematologica | 2020; 105(5)
1435